Zemek, Rachael M. http://orcid.org/0000-0002-0976-6163
Chin, Wee Loong
Fear, Vanessa S. http://orcid.org/0000-0001-8363-6685
Wylie, Ben http://orcid.org/0000-0001-8781-8611
Casey, Thomas H.
Forbes, Cath
Tilsed, Caitlin M.
Boon, Louis
Guo, Belinda B. http://orcid.org/0000-0003-2146-8561
Bosco, Anthony
Forrest, Alistair R. R.
Millward, Michael J.
Nowak, Anna K. http://orcid.org/0000-0002-9317-9526
Lake, Richard A. http://orcid.org/0000-0002-7765-602X
Lassmann, Timo http://orcid.org/0000-0002-0138-2691
Lesterhuis, W. Joost http://orcid.org/0000-0002-2718-276X
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (1103980, 1107043)
Article History
Received: 10 September 2021
Accepted: 6 August 2022
First Online: 19 August 2022
Change Date: 7 October 2022
Change Type: Update
Change Details: In the original version of this article, the given and family names of W. Joost Lesterhuis were incorrectly structured. The name was displayed correctly in all versions at the time of publication. The original article has been corrected.
Competing interests
: Patent application pertaining to aspects of this work: PCT/AU2021/050764. W.J.L.: consultancy Douglas Pharmaceuticals, MSD, research funding Douglas Pharmaceuticals, AstraZeneca, ENA therapeutics. A.K.N. advisory boards Boehringer Ingelheim, Bayer, Roche, BMS; research funding from AstraZeneca. M.M.: Advisory boards MSD, BMS, Roche, AstraZeneca. The remaining authors declare no competing interests.